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Abstract
Background: Elastogenesis of elastic extracellular matrix (ECM) which was recognized as a major
component of blood vessels has been believed for a long time to play only a passive role in the
dynamic vascular changes of typical hypertension. Emilin1 gene participated in the transcription of
ECM's formation and was recognized to modulate links TGF-β maturation to blood pressure
homeostasis in animal study. Recently relevant advances urge further researches to investigate the
role of Emilin1 gene in regulating TGF-β signals involved in elastogenesis and vascular cell defects
of essential hypertension (EH).
Methods: We designed a two-stage case-control study and selected three single nucleotide
polymorphisms (SNPs), rs3754734, rs2011616 and rs2304682 from the HapMap database, which
covered Emilin1 gene. Totally 2,586 subjects were recruited from the International Collaborative
Study of Cardiovascular Disease in Asia (InterASIA). In stage 1, all the three SNPs of the Emilin1
gene were genotyped and tested within a subsample including 503 cases and 490 controls,
significant SNPs would enter into stage 2 including 814 cases with hypertension and 779 controls
and analyze on the basis of testing total 2,586 subjects.
Results:  In stage 1, single locus analyses showed that SNPs rs3754734 and rs2011616 had
significant association with EH (P < 0.05). In stage 2, weak association for dominant model were
observed by age stratification and odds ratio (ORs) of TG+GG vs. TT of rs3754734 were 0.768
(0.584-1.009), 0.985 (0.735-1.320) and 1.346 (1.003-1.806) in < 50, 50-59 and ≥ 60 years group and
ORs of GA+AA vs. GG of rs2011616 were 0.745 (0.568-0.977), 1.013 (0.758-1.353) and 1.437
(1.072-1.926) in < 50, 50-59 and ≥ 60 years group respectively. Accordingly, significant interactions
were detected between genotypes of rs3754734 and rs2011616 and age for EH, and ORs were
1.758 (1.180-2.620), P = 0.006 and 1.903 (1.281-2.825), P = 0.001, respectively. Results of
haplotypes analysis showed that there weren't any haplotypes associated with EH directly, but the
interaction of hap2 (GA) and age-group found to be significant after being adjusted for the
covariates, OR was 1.220 (1.031-1.444), P value was 0.020.
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Conclusion: Our findings don't support positive association of Emilin1 gene with EH, but the
interaction of age and genotype variation of rs3754734 and rs2011616 might increase the risk to
hypertension.
Background
As a major health problem affecting about one third of the
adult worldwide, hypertension mostly arises as a complex
quantitative trait that is affected by varying combinations
of genetic and environmental factors [1,2]. In the majority
of cases, the development of high blood pressure is idio-
pathic being termed essential hypertension[3]. Recently,
studies have highlighted new roles of resistance artery nar-
rowing and large artery stiffening recognized as hallmarks
of essential hypertension, which increase peripheral
resistance and compromise vascular compliance, respec-
tively [4-6].
A series of studies on the pathogenesis of hypertension
have placed major emphasis on smooth muscle and
endothelial cells[4], which are in continuous cross-talk
with each other and formulate dynamic structures of
blood vessels. Remarkably, Elastogenesis of elastic extra-
cellular matrix (ECM), another major component of
blood vessels, has been considered for a long time to play
only a passive role in the dynamic vascular changes of typ-
ical hypertension [2,4,7-9]. Interactions of ECM-cell
named as elastic fibres, together with neurotransmitters
and hormones modulate the structural organization of
the vascular wall and provide the structural framework
and physiological circulatory function through specific
receptors [2]. Therefore, dysfunction of elastic fibres
might be key elements in the pathophysiological changes
of hypertensive vascular remodeling.
EMILIN, which was originally identified in attempts to
isolate ECM, was named for elastin micro fibril interface
located protein for its peculiarly fine distribution on the
surface of amorphous elastin [10]. As a main member of
EMILIN, Emilin1 might play a key role in hypertensive
vascular remodeling [7,9,10]. Transforming growth factor
(TGF)-β proteins are main regulators of blood vessel
development and maintenance, and Emilin1 inhibits
TGF-β signaling by binding specifically to the proTGF-β
precursor and preventing its maturation by furin conver-
tases in the extracellular space [2,8]. Therefore, based on
the proof of Emilin1 modulating TGF-β availability in the
development of cardiovascular system and the pathogen-
esis of hypertension and linking TGF-β maturation to
blood pressure homeostasis identified in animal study,
the discovery of genetic susceptibility of Emilin1 gene to
hypertension will lead to a better understanding of the
mechanism of human hypertension.
In the present study, we conducted a two-stage case-con-
trol study [11] to investigate the associations of common




All the studied subjects were recruited from the Interna-
tional Collaborative Study of Cardiovascular Disease in
Asia (InterASIA in China), from which all the DNA sam-
ples and clinical data for participants were obtained [12].
The local bioethical committee approved the protocol,
and informed consent was obtained from each partici-
pant. InterASIA used a four-stage stratified sampling
method to select a nationally representative sample of the
general population aged 35 to 74 years in China [12,13].
A total of 15,838 persons accepted the survey and exami-
nation. Among these, we enrolled 1,317 unrelated hyper-
tensive patients and 1,269 age and gender-matched
unrelated normotensives from four northern field centers
of InterASIA, namely Beijing, Jilin, Shandong, and Shanxi
province. Three BP measurements were obtained from
each participant by certified observers according to a
standard protocol recommended by the American Heart
Association [14,15].
In this study, hypertensives were selected from those with
systolic BP (SBP) ≥ 150 mmHg, and/or diastolic BP (DBP)
≥ 95 mmHg, or currently administering antihypertensive
medication. Subjects with a clinical history of secondary
hypertension, coronary heart disease or diabetes were
excluded. At the same time, normotensives with SBP <
140 mmHg and DBP < 90 mmHg were selected from the
same target study population as controls.
A two-stage association study of total 2,586 unrelated sub-
jects as main study population was conducted [16]. Cases
with high BP were selected likely to enrich genetic suscep-
tibility [17] by increasing the difference in frequencies of
susceptibility alleles between cases and controls to
improve statistical power. 993 subjects were selected as
stage 1 subsample including 503 hypertensive patients
(SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg) and 490
age- and gender-matched normotensives (SBP < 140
mmHg and DBP < 90 mmHg). In stage 2, subsample
included 814 cases with hypertension and 779 age- and
gender-matched normotensives. Additionally, previous
genomic control analysis revealed no evidence of popula-
tion stratification with this data in previous study [18].BMC Medical Genetics 2009, 10:118 http://www.biomedcentral.com/1471-2350/10/118
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Single nucleotide polymorphisms (SNP) selecting and 
genotyping
Emilin1 gene (Official Symbol: EMILIN1, Gene ID:
11117) was mapped on chromosome 2 p23 and spanned
732, 9 bp with 8 entries exons. We searched the HapMap
data of Han Chinese in Beijing, China (CHB) (http://
www.hapmap.org/, public release up to Mar 2008), and
selected all SNPs from 5 kb upstream of Emilin1 gene to
1 kb downstream. Three SNPs, rs3754734 (-1932G/T) at
5' flanking region, rs2011616 (1031G/A) in intron_1 and
rs2304682 (6239 G/C) in intron 5, were identified. SNP
rs3754734 (-1932G/T) may predict buildups of transcrip-
tion factor (TF) binding sites of Nkx-2 and CdxA accord-
ing to the variation of allele G to T. Function analysis
proceeded on the website of selection tool for single
nucleotide polymorphisms (FASTSNP, http://fast
snp.ibms.sinica.edu.tw) [19] and the risk of rs3754734
for TF binding sites is 1-3. Also, TF binding site of stimu-
lating protein 1 (Sp1) was predicted as an intronic
enhancer for allele G to allele A of rs2011616 and risk is
1-2.
Blood for genotyping was taken into ethylenediamine
tetraacetic acid (EDTA)-containing receptacles. All the 3
entries SNPs were genotyped by polymerase chain reac-
tion/restriction fragment length polymorphism (PCR/
RFLP) protocols. The primers, locations for Emilin1 gene,
alleles, minor allele frequency (MAF), related restriction
endonuclease, as well as digested bands are shown in
table 1. Digested fragments were separated by electro-
phoresis in 3% agarose gel and identified by ethidium
bromide staining. Ninety-six randomly selected individu-
als were genotyped again for quality control with com-
plete concordance and genotyping was done blindly to
the case-control status in Chinese National Human
Genome Center, Beijing.
Statistical Analysis
Unpaired Student's t-test was used to test the differences
of all measured variables presented as the means ± SD
between cases and controls, and one-way ANOVA was
used to test differences in SBP and DBP among genotypes.
In stage 1, single locus analyses were used to test the asso-
ciations between three SNPs and EH. The numbers of alle-
les and genotypes of the SNPs were counted, and their
distributions between the case and control groups were
compared by Chi-square (χ2) test. Hardy-Weinberg equi-
librium (HWE) test were used to detect genotype typing
errors for quality control by Fisher's exact χ2 test using the
program HWE [20]. A forward stepwise (likelihood ratio)
method for multivariate unconditional logistic regression
was applied to adjust for covariates including age, gender,
body mass index (BMI), glucose (Glu), triglycerides (TG),
total cholesterol (TC), high density lipoprotein choles-
terol (HDL-C), low density lipoprotein cholesterol (LDL-
C), creatinine (Cr), smoking and drinking status. The
probability for stepwise entry is 0.05 and that for stepwise
removal is 0.1. The criterion for SNPs entering into stage
2 study was that the SNPs had a two-tailed probability (P)
value of < 0.05 for the comparisons of allele frequencies
or genotype distributions between cases and controls in
stage 1. Bonferroni correction for multiple comparisons
wasn't used in stage 1 because stage 1 served for hypothe-
sis generation. In stage 2, joint analysis was performed in
the main study population for the high efficiency and
power reliability because the power of detecting signifi-
cant association is reduced by using only the samples in
stage 2 [21,22]. Particularly, gene-age interaction was ana-
lyzed with age stratification under 50 years, 50-60 years
and over 60 years.
Multilocus analyses for haplotype (frequency > 5%) were
performed in stage 2. The haplo.glm approach was used
[23] to obtain ORs of risk haplotypes in the multivariable-
adjusted model. Haplo.glm was applied in the haplo.stats
package using R language http://cran.r-project.org/.
Results
Table 2 shows the demographic and clinical characteris-
tics of the subjects included in the stage 1 and stage 2 and
joint population. Age and the percentage of men, drinking
and smoking were not significantly different between
cases and controls in both stage 1 and stage 2. The cases
generally had lower HDL-C and higher BMI, TC, TG, Glu
Table 1: Location region, primer sequences, alleles, MAF and restriction enzymes for Emilin1 gene SNPs
SNPs Emilin1 
region
Primer sequences Alleles Major/Minor MAF Restriction enzymes Digested bands (bp)
Rs3754734 5'fanking F: 5' CGCTCTCACCCACAATACCT 3'
R: 5' TGGCAAATGGTAAATGCTCA 3'
T/G 0.367 Apo I T allele: 191
G allele: 159
Rs2011616 Intron 1 F: 5' TTGACCCCATCCAGTAATC 3'
R: 5'AATAAGCCATTGATGAGCCTGAC 3'
G/A 0.356 Hinf I G allele: 153
A allele: 129
Rs2304682 Intron 5 F: 5' TGCTTTGAAGTCCACGTAGCATC 3'
R: 5' TGGGAAGGGTGGATGTTA 3'
G/C 0.367 Taq I G allele: 256
C allele: 279
Underlined bases were mismatched
F: forward primer, R: reverse primer
MAF: Minor allele frequency.BMC Medical Genetics 2009, 10:118 http://www.biomedcentral.com/1471-2350/10/118
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and Cr levels than the corresponding controls. As
expected, the SBP and DBP levels were both significantly
higher in the cases of stage 1 than those of stage 2 (P val-
ues < 0.0001).
Genotype distributions and allele frequencies for the three
SNPs tested are showed in table 3. All SNPs were in HWE
in cases, controls and combination population. There
were significant differences in rs3754734 and rs2011616
genotypes distributions between cases and controls. Com-
pared with wild-type individuals, both G allele carriers
(TG/GG genotype)of rs3754734 and A allele carriers (GA/
AA genotype)of rs2011616 were at increased risk for EH,
ORs were 1.336(1.013-1.762) and 1.348 (1.035-1.756),
respectively. There weren't significant differences in geno-
type or allele frequencies of rs2304682 between cases and
controls. Therefore, rs3754734 and rs2011616 would be
taken as further hypotheses to test and proceed with the
stage 2 study.
In stage 2, rs3754734 and rs2011616 were genotyped on
the remaining cases and controls and conjoint analysis
was conducted in all 2,586 individuals described as
above. Genotype analysis was not found statistical associ-
ation of rs3754734 and rs2011616 with EH after adjusted
for gender, age, BMI, TC, TG, Cr, HDL-C, LDL-C, Glu,
smoking, drinking (table 3).
In order to evaluate genetic modification effective of age
for Emilin1 gene to EH, subjects were divided into < 50,
50-59 and ≥ 60 years groups in stage 2. The dominant
models (TG+GG vs. TT) of rs3754734 showed negative
correlation to EH in ≥ 60 years group and ORs was 1.346
(1.003-1.806). Compared with GG genotype, GA or AA
genotype of rs2011616 showed a bidirectional effects on
EH in < 50 and ≥ 60 years groups and ORs were 0.745
(0.568-0.977) and 1.437 (1.072-1.926) respectively
(table 4). But there wasn't any statistical difference of
allele distribution found between case and control among
age groups. Accordingly, Logistic regression model (the
entry probability value for stepwise 0.05 and the removal
is 0.1) was used to detect significant interactions between
genotypes of rs3754734 and rs2011616 and age for EH,
and ORs were 1.758 (1.180-2.620), P = 0.006 and
1.903(1.281-2.825), P = 0.001, respectively (table 5).
Pairwise linkage disequilibrium (LD) analysis between
the SNPs was measured by genetic program with R soft-
ware and the value of D' equal to 0.827 between
rs3754734 and rs2011616. To further investigate the
effect of haplotype and interaction in stage 2, haplotypes
were constructed by the two SNPs arranged in the order of
rs3754734 and rs2011616. The frequencies of haplotype
hap1(TG), hap2(GA), hap3(GG) and hap4(TA) were
0.613 (base haplotype), 0.265, 0.088 and 0.033 respec-
tively (except 0.001 for rare haplotype constructed by not
typed genotype). Haplo.glm model was used with R soft-
ware and the results showed that there weren't any haplo-
types associated with EH but the interaction of hap2 and
age-group found to be significant after being adjusted for
Table 2: Comparison of clinical characteristics between cases and controls in stage 1, stage 2 and joint analysis
Stage 1 Stage 2 Joint analysis
Characteristics Cases (n = 503) Controls 
(n = 490)
Cases (n = 814) Controls 
(n = 779)
Cases (n = 1317) Controls 
(n = 1269)
Male (%) 52.1 52.4 48.3 51.5 49.7 51.9
Age (years) 53.6 ± 9.3 53.5 ± 9.2 54.5 ± 10.7 53.5 ± 9.7 54.2 ± 10.2 53.5 ± 9.5
SBP (mmHg) 177.07 ± 28.05* 117.47 ± 11.64 148.98 ± 17.84* 113.81 ± 9.86 159.70 ± 26.13* 115.21 ± 10.72
DBP (mmHg) 104.34 ± 12.28* 75.05 ± 8.00 90.62 ± 9.81* 72.86 ± 7.57 95.85 ± 12.70* 73.69 ± 7.81
BMI (kg/m2) 26.32 ± 3.85* 24.30 ± 3.56 25.79 ± 3.52* 23.85 ± 3.37 26.00 ± 3.67* 24.03 ± 3.43
TC (mg/dl) 198.64 ± 37.50**** 192.46 ± 40.06 197.34 ± 35.82* 188.43 ± 38.15 197.84 ± 36.46* 189.98 ± 38.93
HDL-C (mg/dl) 48.80 ± 11.83*** 51.31 ± 13.07 48.38 ± 11.14* 49.39 ± 11.43 48.54 ± 11.41** 50.13 ± 12.12
LDL-C (mg/dl) 121.28 ± 32.64**** 117.38 ± 32.98 122.08 ± 32.69* 115.81 ± 34.36 121.78 ± 32.66* 116.42 ± 33.83
TG (mg/dl) 150.58 ± 94.21* 126.62 ± 76.42 134.94 ± 65.09* 116.67 ± 55.37 140.92 ± 77.85* 120.51 ± 64.47
Glu (mg/dl) 106.77 ± 32.40* 99.09 ± 18.77 97.28 ± 10.90* 94.80 ± 11.55 100.90 ± 22.25* 96.46 ± 14.91
Cr (μmol/l) 70.83 ± 15.21**** 68.92 ± 12.12 70.92 ± 13.34 71.03 ± 12.93 70.89 ± 14.08 70.21 ± 12.66
Smokers (%) 40.6 43.1 39.7 43.0 40.0 43.0




*P < 0.0001 for comparison with corresponding controls
**P < 0.001 for comparison with corresponding controls
***P < 0.01 for comparison with corresponding controls
****P < 0.05 for comparison with corresponding controls
 P < 0.0001 for comparison with corresponding variables in stage 2BMC Medical Genetics 2009, 10:118 http://www.biomedcentral.com/1471-2350/10/118
Page 5 of 8
(page number not for citation purposes)
the covariates above, OR was 1.220(1.031-1.444), P value
was 0.020.
Additionally, the comparisons of quantitative trait for
blood pressure were processed among genotypes. Normal
test indicated that blood pressure presented approximate
normal distribution. The results of one-way ANOVA
showed that the differences of SBP and DBP in treatment
(n = 448) [24] and DBP in non-treatment groups (n =
2115) were significant between genotypes of rs3754734
(table 6). But no significant alterations of SBP or DBP
were found between the genotypes of rs2011616.
Discussion
Emilin1 gene was located in 2p23.3-p23.2. As a member
of EMILINs, which are a new family of glycoprotein's of
the extracellular matrix [25], Emilin1 localized at the
interface between amorphous elastin and microfibril and
played an important role in embryonic development [26],
blood pressure homeostasis by linking TGF-β maturation
[2,7], elastogenesis and vascular cell defects [9]. The gC1q
domain of Emilin1 can form relatively stable and compact
homotrimers, and then be followed by a multimeric
assembly of disulfide-bonded protomers. The transcrip-
tion of Emilin1 in different tissues is probably achieved
through combinatorial cooperation between various
regions, rather than being dependent on a single cis-acti-
vating region specific for each tissue [27]. Emilin1 code
for a secreted proteins whose hallmark is the presence of
a cysteine-rich motif defined as EMI domain [28] that fol-
lowed by a coiled-coil, a short collagenous domain, and a
C1q-like repeat at the C terminus which has been shown
that the C-terminal domain is involved in the oligomeri-
zation of Emilin1, cell adhesion and modulating growth
factors' activity [29].
Table 3: Genotype distributions and allele frequencies of the three SNPs tested in stage 1 and stage 2
SNP Group Genotype Allele
WT Ht+MT ORa (95%CI) Pa Major/Minor OR (95%CI) P
Stage 1 rs3754734 TT TG+GG T/G
Case 153 261+89 0.564/0.436
Control 188 214+88 1.336(1.013-1.762) 0.040 0.602/0.398 1.17(0.98-1.40) 0.082
rs2011616 GG GA+AA G/A
Case 244 214+43 0.701/0.299
Control 270 181+39 1.348(1.035-1.756) 0.027 0.736/0.264 1.19(0.98-1.45) 0.082
rs2304682 GG GC+CC G/C
Case 245 213+45 0.699/0.301
Control 251 196+43 1.034(0.796-1.343) 0.840 0.712/0.288 1.07(0.88-1.29) 0.511
Stage 2 rs3754734 TT TG+GG T/G
Case 522 598+164 0.648/0.352
Control 533 570+163 0.980(0.832-1.155) 0.811 0.646/0.354 0.992(0.885-1.112) 0.894
rs2011616 GG GA+AA G/A
Case 643 555+109 0.704/0.296
Control 608 541+110 1.004(0.853-1.181) 0.963 0.698/0.302 1.032 (0.915-1.163) 0.611
a. Adjusted for gender, age, BMI, TC, TG, Cr, HDL-C, LDL-C, Glu, smoking, drinking.
WT wide type, Ht heterozygote, MT mutant type
Table 4: Analysis of age stratified association of rs3754734 and rs2011616 with hypertension in stage 2.
SNP Age group (years) Genotype Allele (Major/Minor)
Case Control OR*(95%CI) P case control OR (95%CI) P
rs3754734 TT/TG/GG TT vs. TG/GG T/G T/G
< 50 217/193/58 188/220/59 0.768(0.584-1.009) 0.058 0.670/0.330 0.638/0.362 0.87(0.72-1.06) 0.174
50-60 161/183/48 172/191/55 0.985(0.735-1.320) 0.919 0.644/0.356 0.640/0.360 1.02(0.83-1.25) 0.876
> 60 175/222/58 173/159/49 1.346(1.003-1.806) 0.048 0.629/0.371 0.663/0.337 0.86(0.70-1.05) 0.151
rs2011616 GG/GA/AA GG vs. GA/AA G/A G/A
< 50 245/177/41 212/213/38 0.745(0.568-0.977) 0.033 0.720/0.280 0.688/0.312 1.17(0.96-1.43) 0.126
50-60 182/170/40 195/187/33 1.013(0.758-1.353) 0.932 0.681/0.319 0.695/0.305 0.94(0.76-1.16) 0.543
> 60 216/208/28 201/141/39 1.437(1.072-1.926) 0.015 0.708/0.292 0.713/0.287 0.98(0.79-1.21) 0.835
*: Adjusted by gender, BMI, TC, TG, Cr, HDL-C, LDL-C, Glu, smoking, drinking.BMC Medical Genetics 2009, 10:118 http://www.biomedcentral.com/1471-2350/10/118
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Zanetti et al. [2,9] proved that an unprecedented link
between TGF-β signaling and arterial hypertension was
based on the analysis of mice mutant for Emilin1, which
genetic inactivation would induce TGF-β signaling up-reg-
ulation in the vascular wall and further cause blood pres-
sure increasing. Therefore, the findings reported stimulate
further study to replicate in human and we designed the
present study to explore the association of Emilin1 gene
with EH in a northern Han Chinese population.
With the purpose of rationality and availabiliy in research,
we mainly considered the following approaches. First, we
focused on a segment located from 5 kb upstream of
Emilin1 gene to 1 kb downstream and mainly aimed at
SNPs with a minimum MAF ≥ 0.05. We searched HapMap
database of CHB recently published and found three SNPs
with available MAF. We tested all those three SNPs in
present study rather than general haplotype-tagging meth-
ods for selecting SNPs as Bhatti described [12]. Second, we
applied a two-stage study to test the association of
Emilin1 gene with EH. As well known, two-stage study
provides a practical cost-effective strategy for association
studies and full set of SNPs genotyping is performed in the
first stage in a fraction (allocate 1/3 to 1/2) of the total
number of samples for screening [21,22]. In addition, the
hypertensive cases with higher BP level in stage 1 were
likely to be enriched genetic susceptibility and might
increase power to test the association of Emilin1 gene
with EH [16].
Blood pressure has long been known to be a complex trait
influenced by both genetic and environmental factors
[30]. A large number of genes are potentially involved in
blood pressure regulation and even the susceptibility to
hypertension, and the effects of these genes may be mod-
ulated by age [31,32]. Age-genetic effects for complex
traits, such as hypertension [33-35], can prevent replica-
tions if the age-varying character of an association is not
taken into account in the selection of both the replication
samples and the statistical analysis strategy [34]. Because
age is a complex biological construction, it may serve as a
surrogate for a variety of interacting covariates and which
may not only enhance gene discovery, but also render
findings from across studies more comparable to each
other [32]. As well known, for subjects over 50 years of
age, SBP and DBP increase exponentially with age [36], so
we divided age into < 50, 50-60 and ≥ 60 years groups and
this age stratification may help estimate the ages at which
subjects should be studied to maximize the expression of
the genetic effect and increase the power of association
studies for various phenotypes [31,34,36].
In the present study, our results showed that two SNPs,
rs3754734 and rs2011616 had significant association
with EH in stage 1. But association analyses for replicated
authentication in stage 2 showed that the significant asso-
ciations hadn't been repeated directly. Some reasons as
follow probably contribute to this disaccord. Firstly, the
blood pressure levels of cases in sample 2 were lower than
Table 5: Analysis of interaction of gene and age for EH.
Genotype Age group (years) β Standard error P OR (95% CI)
Rs3754734 TG/GG < 50 - - - 1.00
(TG/GG vs. TT) TG/GG 50-60 vs. < 50 0.252 0.203 0.215 1.286(0.864-1.916)
TG/GG > 60 vs. < 50 0.564 0.204 0.006 1.758 (1.180-2.620)
rs2011616 GA/AA < 50 - - - 1.00
(GA/AA vs. GG) GA/AA 50-60 vs. < 50 0.315 0.202 0.118 1.371(0.923-2.035)
GA/AA > 60 vs. < 50 0.643 0.202 0.001 1.903(1.281-2.825)
*: Adjusted by gender, BMI, TC, TG, Cr, HDL-C, LDL-C, Glu, smoking, drinking.
Table 6: Comparisons of quantitative traits of blood pressure between genotypes of rs3754734 and 2011616 by treatment 
stratification
rs3754734 rs2011616
Group TT TG GG GG GA AA
Treatment (n) 196 200 52 225 190 33
SBP (mmHg) 174.03 ± 25.73 176.24 ± 20.72 184.20 ± 22.41* 177.55 ± 25.95 174.78 ± 20.62 176.08 ± 18.89
DBP (mmHg) 102.45 ± 10.75 103.64 ± 9.55 105.93 ± 10.50* 103.53 ± 10.94 103.11 ± 9.49 104.87 ± 9.57
Non-treatment (n) 881 960 274 1025 906 186
SBP (mmHg) 126.91 ± 21.15 128.65 ± 24.26 128.42 ± 20.86 127.60 ± 21.67 128.38 ± 22.52 127.54 ± 27.56
DBP (mmHg) 79.72 ± 12.23 80.19 ± 12.87 81.66 ± 12.37* 80.37 ± 12.48 79.98 ± 12.77 80.57 ± 12.08
P > 0.05 for all test of homogeneity of variances
*P < 0.05 for linear term testBMC Medical Genetics 2009, 10:118 http://www.biomedcentral.com/1471-2350/10/118
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sample 1 so that the association strength was decrease in
joint sample and hardly detected. Secondly, false positive
association presented in stage 1 was rooted in potential
differentiation for covariates or population structure in
the two samples. Thirdly, genetic heterozygosity arose
from the inner of research population might devote differ-
ent susceptibility to EH in subgroups. Also, phenocopy for
other disease often falsified results in association study.
Finally, information bias including measurement bias,
recall bias, misclassification, etc. often distort results for
epidemiological association studies. Further age-stratified
analysis and interaction detection showed that the varia-
tions of Emilin1 gene might influence the susceptibility to
EH via age modulating way. Accordance to the biologi-
cally plausibility described as reported above, it would be
helpful to interpret that whether potential biological roles
of rs3754734 on transcriptional control and rs2011616
on TF binding sites would affect the susceptibility altera-
tion to EH or blood pressure homeostasis in human.
In conclusion, our finding suggests age modulated associ-
ation between the genetic variation of Emilin1 gene and
blood pressure ascending and that would stimulate fur-
ther investigation of the role of Emilin1 gene in vascular
development and blood pressure homeostasis. Mean-
while, it is worthwhile to find the biological function of
Emlin1 in signal transforming and regulating pathway
involved in blood advance[37]. Additionally, the Emlin1
sequencing or searching SNPs data of other races would
provide more SNPs to select except for following interests
in SNPs with MAF < 0.05 or other variants farther away
from Emilin1 gene to provide rationality support [38,39].
Conclusion
Our findings support that the Emilin1 gene had an age
modulated interaction on the risk to EH and further repli-
cations in other populations and functional studies
should be warranted.
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